{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:16:03Z","timestamp":1793164563716,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05558-9","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T10:23:55Z","timestamp":1710843835000},"page":"2213-2225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6039-5665","authenticated-orcid":false,"given":"Justin","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-5673","authenticated-orcid":false,"given":"Varinder","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-2790","authenticated-orcid":false,"given":"Elaine","family":"Yacyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1228-0623","authenticated-orcid":false,"given":"Azin","family":"Rouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0826-1649","authenticated-orcid":false,"given":"Monika","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"issue":"8","key":"5558_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347(8):589\u2013600. https:\/\/doi.org\/10.1056\/NEJMra020528","journal-title":"N Engl J Med"},{"issue":"3","key":"5558_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","volume":"60","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60(3):831\u2013846. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060003831.x","journal-title":"Kidney Int"},{"issue":"2","key":"5558_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0046-8177(86)80293-3","volume":"17","author":"AB Magil","year":"1986","unstructured":"Magil AB, McFadden D, Rae A (1986) Lupus glomerulonephritis with thrombotic microangiopathy. Hum Pathol 17(2):192\u2013194. https:\/\/doi.org\/10.1016\/S0046-8177(86)80293-3","journal-title":"Hum Pathol"},{"issue":"4","key":"5558_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-001-0153-z","volume":"21","author":"C-H Tsao","year":"2002","unstructured":"Tsao C-H, Hsueh S, Huang J-L (2002) Initial presentation of hemolytic uremic syndrome in a boy with systemic lupus erythematosus. Rheumatol Int 21(4):161\u2013164. https:\/\/doi.org\/10.1007\/s00296-001-0153-z","journal-title":"Rheumatol Int"},{"issue":"5\u20136","key":"5558_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1159\/000065286","volume":"22","author":"Y Kawasaki","year":"2002","unstructured":"Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H (2002) A 12-year-old girl with hemolytic uremic syndrome as initial symptom of systemic lupus erythematosus and a literature review. Am J Nephrol 22(5\u20136):576\u2013580. https:\/\/doi.org\/10.1159\/000065286","journal-title":"Am J Nephrol"},{"key":"5558_CR6","unstructured":"Rabbani, M. A., Ahmad, B., Mekan, S. F., Muzaffar, S., & Ali, S. S. (2005). Systemic lupus erythematosus presenting as hemolytic uremic syndrome: A case report. JPMA. The Journal of the Pakistan Medical Association, 55(2), 84\u201387."},{"key":"5558_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11255-010-9754-3","volume":"43","author":"N Leban","year":"2010","unstructured":"Leban N, Aloui S, Touati D, Lakhdhar R, Skhiri H, Lefranc G, Achour A, Elmay M, L\u00f3pez-Trascasa M, Sanchez-Corral P, Chibani J, Khelil A (2010) Atypical hemolytic uremic syndrome in the Tunisian population. Int Urol Nephrol 43:559\u2013564. https:\/\/doi.org\/10.1007\/s11255-010-9754-3","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"5558_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1445-5994.2011.02591.x","volume":"42","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Leguy V, Berthier S, Janikashvili N, Martin L, Bonnotte B, Lorcerie B (2012) Haemolytic-uraemic syndrome during severe lupus nephritis: Efficacy of plasma exchange. Intern Med J 42(1):95\u201398. https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02591.x","journal-title":"Intern Med J"},{"issue":"5","key":"5558_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/0961203307077151","volume":"16","author":"BJ Hunt","year":"2007","unstructured":"Hunt BJ, Tueger S, Pattison J, Cavenagh J, D\u2019Cruz DP (2007) Microangiopathic haemolytic anaemia secondary to lupus nephritis: An important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus 16(5):358\u2013362. https:\/\/doi.org\/10.1177\/0961203307077151","journal-title":"Lupus"},{"key":"5558_CR10","doi-asserted-by":"publisher","unstructured":"Taktak, A., K\u00f6ksoy, A., Ba\u015faran, \u00d6., Kiremit\u00e7i, S., Acar, B., Uncu, N., & \u00c7akar, N. (2016). An unexpected diagnostic course of systemic lupus erythematosus. The Turkish Journal of Pediatrics, 58(2), 223\u2013226. https:\/\/doi.org\/10.24953\/turkjped.2016.02.018","DOI":"10.24953\/turkjped.2016.02.018"},{"issue":"1","key":"5558_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","volume":"49","author":"N Kello","year":"2019","unstructured":"Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL (2019) Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 49(1):74\u201383. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5558_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s004670050016","volume":"14","author":"T Ogawa","year":"2000","unstructured":"Ogawa T, Arai H, Maruyama K, Watanabe T, Kobayashi Y, Kikuchi O, Morikawa A (2000) Association of systemic lupus erythematosus and hemolytic uremic syndrome in a child. Pediatric Nephrology (Berlin, Germany) 14(1):62\u201364. https:\/\/doi.org\/10.1007\/s004670050016","journal-title":"Pediatric Nephrology (Berlin, Germany)"},{"issue":"3","key":"5558_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000045811","volume":"86","author":"S Al Shohaib","year":"2000","unstructured":"Al Shohaib S, Karsou S, Al Ghamdi S (2000) Hemolytic-uremic syndrome superimposed on chronic lupus nephritis. Nephron 86(3):380. https:\/\/doi.org\/10.1159\/000045811","journal-title":"Nephron"},{"issue":"4","key":"5558_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ccr3.1425","volume":"6","author":"RZ Attar","year":"2018","unstructured":"Attar RZ, Ramel EI, Safdar OY, Desoky S (2018) A case of patient with renal lupus with an initial presentation of hemolytic uremic syndrome triggered by streptococcal infection. Clin Case Rep 6(4):712\u2013718. https:\/\/doi.org\/10.1002\/ccr3.1425","journal-title":"Clin Case Rep"},{"issue":"16","key":"5558_CR15","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park MH, Caselman N, Ulmer S, Weitz IC (2018) Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2(16):2090\u20132094. https:\/\/doi.org\/10.1182\/bloodadvances.2018019596","journal-title":"Blood Adv"},{"issue":"11","key":"5558_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2169\/internalmedicine.0228-17","volume":"57","author":"M Ono","year":"2018","unstructured":"Ono M, Ohashi N, Namikawa A, Katahashi N, Ishigaki S, Tsuji N, Isobe S, Iwakura T, Sakao Y, Tsuji T, Kato A, Fujigaki Y, Shimizu A, Yasuda H (2018) A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome. Internal Med (Tokyo, Japan) 57(11):1617\u20131623. https:\/\/doi.org\/10.2169\/internalmedicine.0228-17","journal-title":"Internal Med (Tokyo, Japan)"},{"key":"5558_CR17","doi-asserted-by":"publisher","unstructured":"de Holanda, M. I., P\u00f4rto, L. C., Wagner, T., Christiani, L. F., & Palma, L. M. P. (2017). Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clinical Rheumatology, 36(12), 2859\u20132867. https:\/\/doi.org\/10.1007\/s10067-017-3823-2","DOI":"10.1007\/s10067-017-3823-2"},{"issue":"2","key":"5558_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","volume":"55","author":"S Wig","year":"2016","unstructured":"Wig S, Chan M, Thachil J, Bruce I, Barnes T (2016) A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford) 55(2):382\u2013384. https:\/\/doi.org\/10.1093\/rheumatology\/kev371","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5558_CR19","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.4081\/hr.2016.6625","volume":"8","author":"AG Raufi","year":"2016","unstructured":"Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran M-H (2016) Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis. Responsive Eculizumab Hematol Rep 8(3):6625. https:\/\/doi.org\/10.4081\/hr.2016.6625","journal-title":"Responsive Eculizumab Hematol Rep"},{"issue":"1","key":"5558_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","volume":"65","author":"A El-Husseini","year":"2015","unstructured":"El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2015) Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab. Am J Kidney Dis 65(1):127\u2013130. https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.031","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"5558_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000143","volume":"93","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler A, Frank R, Kirschfink M, Szil\u00e1gyi \u00c1, Csuka D, Proh\u00e1szka Z, Schratzberger P, Lhotta K, Mayer G (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine 93(26):e143. https:\/\/doi.org\/10.1097\/MD.0000000000000143","journal-title":"Medicine"},{"issue":"8","key":"5558_CR22","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE (2012) Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64(8):2719\u20132723. https:\/\/doi.org\/10.1002\/art.34440","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5558_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatric Nephrol (Berlin, Germany) 30(1):167\u2013172. https:\/\/doi.org\/10.1007\/s00467-014-2944-y","journal-title":"Pediatric Nephrol (Berlin, Germany)"},{"issue":"12","key":"5558_CR24","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/rheumatology\/kev307","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Terence Cook H, Cairns TD (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54(12):2286\u20132288. https:\/\/doi.org\/10.1093\/rheumatology\/kev307","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5558_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/RHU.0000000000000423","volume":"22","author":"RS Bermea","year":"2016","unstructured":"Bermea RS, Sharma N, Cohen K, Liarski VM (2016) Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol 22(6):320\u2013323. https:\/\/doi.org\/10.1097\/RHU.0000000000000423","journal-title":"J Clin Rheumatol"},{"key":"5558_CR26","doi-asserted-by":"publisher","unstructured":"AlGhobaishi, A., Mousa, A. H., Alshaltoni, R. S., Mohsen, A. S., Baothman, A., Adem, H., Eisa, Y., Amin, A., & Edrees, B. (2022). Two concomitant thrombotic microangiopathies in the background of systemic lupus erythematosus: A case report. Annals of Medicine and Surgery (2012), 81, 104541. https:\/\/doi.org\/10.1016\/j.amsu.2022.104541","DOI":"10.1016\/j.amsu.2022.104541"},{"issue":"5","key":"5558_CR27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25117","volume":"14","author":"I Alhamoud","year":"2022","unstructured":"Alhamoud I, Freiberg SA (2022) Successful discontinuation of eculizumab in a pediatric patient with atypical hemolytic uremic syndrome and underlying systematic lupus erythematosus. Cureus 14(5):e25117. https:\/\/doi.org\/10.7759\/cureus.25117","journal-title":"Cureus"},{"issue":"5","key":"5558_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.5527\/wjn.v4.i5.528","volume":"4","author":"D Blum","year":"2015","unstructured":"Blum D, Blake G (2015) Lupus-associated thrombotic thrombocytopenic purpura-like microangiopathy. World J Nephrol 4(5):528\u2013531. https:\/\/doi.org\/10.5527\/wjn.v4.i5.528","journal-title":"World J Nephrol"},{"issue":"1","key":"5558_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12882-021-02293-2","volume":"22","author":"MJ Kim","year":"2021","unstructured":"Kim MJ, Lee H, Kim YH, Jin SY, Kim H-J, Oh D, Jeon JS (2021) Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 22(1):86. https:\/\/doi.org\/10.1186\/s12882-021-02293-2","journal-title":"BMC Nephrol"},{"issue":"3","key":"5558_CR30","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1093\/rheumatology\/keaa474","volume":"60","author":"C-F Su","year":"2021","unstructured":"Su C-F, Liao H-T, Tsai C-Y (2021) WT1 gene mutations in systemic lupus erythematosus with atypical haemolytic uremic syndrome. Rheumatology (Oxford) 60(3):e81\u2013e82. https:\/\/doi.org\/10.1093\/rheumatology\/keaa474","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5558_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000512227","volume":"11","author":"EA Torres","year":"2021","unstructured":"Torres EA, Chang Y, Desai S, Chang I, Zuckerman JE, Burwick R, Kalantar-Zadeh K, Hanna RM (2021) Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report. Case Rep Nephrol Dialysis 11(1):95\u2013102. https:\/\/doi.org\/10.1159\/000512227","journal-title":"Case Rep Nephrol Dialysis"},{"issue":"6","key":"5558_CR32","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","volume":"95","author":"M Praga","year":"2019","unstructured":"Praga M, Rodr\u00edguez De C\u00f3rdoba S (2019) Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney Int 95(6):1298\u20131300. https:\/\/doi.org\/10.1016\/j.kint.2019.01.043","journal-title":"Kidney Int"},{"issue":"2","key":"5558_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.RV17026","volume":"26","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y, Nangaku M (2019) Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 26(2):99\u2013110. https:\/\/doi.org\/10.5551\/jat.RV17026","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"5558_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/MOP.0b013e32835df48a","volume":"25","author":"C Joseph","year":"2013","unstructured":"Joseph C, Gattineni J (2013) Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 25(2):209\u2013215. https:\/\/doi.org\/10.1097\/MOP.0b013e32835df48a","journal-title":"Curr Opin Pediatr"},{"issue":"16","key":"5558_CR35","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","volume":"123","author":"SR Cataland","year":"2014","unstructured":"Cataland SR, Wu HM (2014) How I treat: The clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123(16):2478\u20132484. https:\/\/doi.org\/10.1182\/blood-2013-11-516237","journal-title":"Blood"},{"key":"5558_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","volume":"7","author":"ACL Macedo","year":"2016","unstructured":"Macedo ACL, Isaac L (2016) Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 7:55. https:\/\/doi.org\/10.3389\/fimmu.2016.00055","journal-title":"Front Immunol"},{"key":"5558_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1546-0096-10-21","volume":"10","author":"A Belot","year":"2012","unstructured":"Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: New insights into SLE pathogenesis. Pediatr Rheumatol Online J 10:21. https:\/\/doi.org\/10.1186\/1546-0096-10-21","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"5558_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000431278","volume":"1","author":"L Bao","year":"2015","unstructured":"Bao L, Cunningham PN, Quigg RJ (2015) Complement in Lupus Nephritis: New Perspectives. Kidney Diseases (Basel, Switzerland) 1(2):91\u201399. https:\/\/doi.org\/10.1159\/000431278","journal-title":"Kidney Diseases (Basel, Switzerland)"},{"issue":"2","key":"5558_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1681\/ASN.2010060647","volume":"22","author":"L Bao","year":"2011","unstructured":"Bao L, Haas M, Quigg RJ (2011) Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22(2):285\u2013295. https:\/\/doi.org\/10.1681\/ASN.2010060647","journal-title":"J Am Soc Nephrol"},{"key":"5558_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.621609","volume":"7","author":"M-H Tseng","year":"2021","unstructured":"Tseng M-H, Fan W-L, Liu H, Yang C-Y, Ding J-J, Lee H-J, Huang S-M, Lin S-H, Huang J-L (2021) Complement factor I mutation may contribute to development of thrombotic microangiopathy in lupus nephritis. Front Med 7:621609. https:\/\/doi.org\/10.3389\/fmed.2020.621609","journal-title":"Front Med"},{"key":"5558_CR41","unstructured":"Furie, R., Matis, L., Rollins, S., & Mojcik, C. (2004). Abstracts of the American College of Rheumatology 68th annual meeting and the Association of Rheumatology Health Professionals 39th annual meeting. October 16-21, 2004, San Antonio, Texas, USA. Arthritis and Rheumatism, 50(9 Suppl), S35-747"},{"issue":"5","key":"5558_CR42","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"issue":"23","key":"5558_CR43","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome. New Engl J Med 368(23):2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"New Engl J Med"},{"issue":"18","key":"5558_CR44","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A-L, Ville S, Pouteil-Noble C, Coindre J-P, Le Quintrec M, Rondeau E, Boyer O, Prov\u00f4t F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Ch\u00e2telet V, Fr\u00e9meaux-Bacchi V (2021) Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137(18):2438\u20132449. https:\/\/doi.org\/10.1182\/blood.2020009280","journal-title":"Blood"},{"issue":"1","key":"5558_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Prov\u00f4t F, Delmas Y, Barbet C, Ch\u00e2telet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre J-P, Rondeau E, Loirat C, Fr\u00e9meaux-Bacchi V (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 12(1):50\u201359. https:\/\/doi.org\/10.2215\/CJN.06440616","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"5558_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A (2022) Avacopan: First Approval. Drugs 82(1):79\u201385. https:\/\/doi.org\/10.1007\/s40265-021-01643-6","journal-title":"Drugs"},{"key":"5558_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103477","volume":"70","author":"Y Deng","year":"2021","unstructured":"Deng Y, Zheng Y, Li D, Hong Q, Zhang M, Li Q, Fu B, Wu L, Wang X, Shen W, Zhang Y, Chang J, Song K, Liu X, Shang S, Cai G, Chen X (2021) Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine 70:103477. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103477","journal-title":"EBioMedicine"},{"issue":"7","key":"5558_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"issue":"10","key":"5558_CR49","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","volume":"7","author":"AS Bomback","year":"2022","unstructured":"Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, Trapani AJ, Smith RJH (2022) Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int Rep 7(10):2150\u20132159. https:\/\/doi.org\/10.1016\/j.ekir.2022.07.004","journal-title":"Kidney Int Rep"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T02:03:32Z","timestamp":1726193012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5558"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05558-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"7 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the \u201cConflict of Interest Disclosure Form\u201d. The authors JS, VH, EY, and AZ declare no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.\u00a0MO declares advisory board honoraria from Alexion, Takeda,\u00a0Sobi, Novartis, Sanofi, Roche, travel support from Alexion and Sobi, speaking honoraria from Alexion and Roche, and the following clinical trial involvement: Alexion (ALXN1210-301, ALXN2040-301); Apellis (APL2-307).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}